Amatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.

Anti-Mesothelin Antibody (BMS-986148 Naked Antibody) is a human monoclonal antibody targeting mesothelin and can be used for the synthesis of the ADC BMS-986148.

Anti-Mesothelin Antibody (such as Amatuximab/MORAb-009) is a chimeric monoclonal antibody targeting mesothelin (MSLN). Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is overexpressed in various malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, while exhibiting restricted expression in normal tissues. The antibody binds to mesothelin with high affinity, and its mechanisms of action primarily include: 1. Blocking the interaction between mesothelin and MUC16 (CA125), thereby inhibiting tumor cell adhesion and metastasis; 2. Inducing direct tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). In basic research, it is widely utilized to evaluate the therapeutic efficacy of targeting mesothelin and for the development of antibody-drug conjugates (ADCs).

Anti-Human MSLN Antibody (Clone HN1) is a humanised monoclonal antibody targeting MSLN (Mesothelin), composed of the mesothelin-specific HN1, which blocks the interaction between MSLN and CA125 with cancer cells, and can be used for cancer research.

Inezetamab is a bispecific monoclonal antibody functioning as an MSLN inhibitor and CD40 agonist, suitable for investigating solid tumours.

Anti-Mesothelin Antibody (YP218) is a chimeric rabbit IgG antibody that targets human Mesothelin.

Mistatug is a chimeric antibody of the IgG1κ type that targets MSLN, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.

Anetumab-MMAE, an ADC, combines a Mesothelin-targeting antibody with Monomethyl auristatin E (MMAE) and is employed in researching advanced pancreatic cancer.